For lab leaders and informatics teams navigating a long-term platform decision

‍

There's a version of the IMS selection process that treats it like a commodity purchase: gather requirements, shortlist vendors, compare feature checklists, negotiate pricing, decide. Treat it like enterprise software procurement, and move on.

The labs that have been through a painful IMS migration — or that are currently working around the limitations of a platform they've outgrown — know that framing is wrong. An IMS is not a line-item decision. It's a strategic one. The platform you choose shapes which scanners you can realistically operate, which analysis tools you can access, how your pathologists experience their work every day, whether your organization can meet its compliance obligations, and how much freedom you'll have to evolve as the field changes.

Get it right, and your IMS becomes a competitive advantage: the infrastructure that lets you scale confidently, adopt new technologies without disruption, and serve clients or internal stakeholders with capabilities your peers are still working toward. Get it wrong, and you'll spend years managing workarounds — until the cost of staying on the wrong platform finally exceeds the cost of migrating off it.

This article explains why the IMS decision carries so much downstream weight, and what it means to choose strategically rather than opportunistically.

The IMS is where every other investment converges

To understand why the IMS decision is so consequential, start with what the IMS actually touches.

Every image your scanners produce flows into the IMS. Every analysis result your quantification tools generate is stored and surfaced through the IMS. Every time a pathologist, scientist, study director, or sponsor accesses your digital slides, they do it through the IMS. Every audit trail entry, every annotation, every collaboration workflow — the IMS is where all of it lives.

This centrality is what makes the IMS different from any other component in the stack. A scanner is a production input. An analysis tool is a processing layer. A LIMS is a system of record. The IMS is the operational environment in which digital pathology actually happens.

Substitute a weak IMS and the effect isn't localized — it propagates. An IMS that can't ingest images from certain scanner formats forces a choice between the scanner you want and the software you have. An IMS with limited integration capabilities turns every analysis workflow into a manual handoff. An IMS without robust compliance tooling means that GLP or GCP requirements have to be met through workarounds, if they can be met at all. An IMS with poor user experience means pathologists resist adoption, and the productivity gains you expected from going digital fail to materialize.

The IMS amplifies or constrains everything around it. That's the strategic reality of the decision.

For a deeper look at the IMS as part of your workflow, see our article on the complete digital pathology stack.

Five ways your IMS choice shapes your strategy

1. Your IMS determines your scanner flexibility

Scanner technology is evolving rapidly. The best available whole slide scanner today will be superseded. New modalities — multiplexed immunofluorescence, spatial transcriptomics, 3D imaging — are expanding what "scanning" means and what the resulting files look like. Labs that want to stay at the leading edge of imaging need the freedom to adopt new scanner technology as it emerges.

That freedom depends almost entirely on your IMS.

Most scanners produce images in proprietary formats. If your IMS only supports a narrow range of formats — or was validated specifically around a single scanner vendor's output — your scanner options are constrained by your software, not by the capabilities of the hardware market. Conversely, an IMS built around open standards and broad format compatibility lets you choose scanners on their merits: throughput, image quality, modality support, cost. You're not locked in.

This matters not just for future scanner purchases, but for labs that already operate multiple scanners from different vendors and different sites — a common situation as labs scale or acquire new capabilities. An IMS that handles heterogeneous scanner environments without friction is a strategic asset. One that requires proprietary format conversion or doesn't support certain vendor outputs creates ongoing operational overhead.

2. Your IMS defines your analysis tool options

The image analysis landscape is one of the most dynamic areas in digital pathology. AI-powered detection, quantification, and classification tools are evolving quickly, and the tools that represent best-in-class capability today may be different in three years. Labs that want access to the best available analysis capabilities — now and in the future — need an IMS that doesn't force them to choose between their infrastructure and their tools.

This is a real risk. IMS platforms that offer tightly coupled proprietary analysis tools — or that have limited third-party integration capabilities — create a de facto lock-in: using the IMS means using its analysis ecosystem, even if better alternatives exist elsewhere.

An IMS with open, well-documented APIs and a track record of expanding its integration library offers something different: the ability to plug in new analysis tools as they emerge, without rebuilding your workflow infrastructure to accommodate them. For labs investing in AI model development, this flexibility is even more important — the annotations your pathologists create today should be portable assets that can feed any analysis platform, not proprietary data locked inside a single vendor's system.

3. Your IMS sets the ceiling on your compliance posture

For labs operating under GLP, GCP, or 21 CFR Part 11 — and for CROs whose clients require documented evidence of regulatory compliance — the IMS is the system most directly implicated in meeting those standards. Audit trails, access controls, data integrity assurances, validation documentation: all of these capabilities need to live in the IMS, because the IMS is where regulated work happens.

The critical point here is that compliance is not something you can configure your way into after the fact. An IMS is either built to meet regulatory standards or it isn't. Audit trail completeness, for example, isn't a feature you can add with a plugin — it requires that the system was architected from the ground up to capture and preserve the right events. The same is true for electronic signature workflows, access control granularity, and the documentation required for a validated system.

Choosing an IMS without validated compliance capabilities and then attempting to meet GLP or GCP requirements through manual compensating controls is both operationally costly and fragile. It also creates risk: when a regulatory inspection or client audit examines your data integrity practices, the gap between "we have workarounds" and "our system is validated" is not a subtle one.

Conversely, an IMS with mature compliance infrastructure removes a significant category of organizational risk — and increasingly, it's a prerequisite for competing for regulated work at all.

4. It determines how your team actually works

Strategy is often discussed in terms of platforms, integrations, and compliance frameworks. But there's a dimension of the IMS decision that is less abstract and more immediate: how do your pathologists and scientists actually experience their work every day?

The IMS is the primary interface between your team and your digital data. The quality of the image viewer, the efficiency of navigation tools, the intuitiveness of annotation and markup features, the speed with which slides load and render — these aren't aesthetic preferences. They are productivity variables with direct impact on study throughput, review accuracy, and pathologist satisfaction.

Labs that have migrated from one IMS to another frequently report that end-user experience was the dimension they underweighted in their original selection. An IMS that pathologists find slow, unintuitive, or frustrating to navigate doesn't just create friction — it generates resistance to digital adoption, which undermines the entire rationale for going digital in the first place. In some cases it results in pathologists reverting to glass-based review for as long as glass is available, which defeats the purpose of the investment.

The strategic implication: end-user experience evaluation — hands-on, by the people who will actually use the platform, in workflows that reflect their real work — should be a first-class component of the IMS selection process, not an afterthought.

5. It shapes your ability to collaborate across sites and stakeholders

Modern digital pathology workflows are rarely confined to a single building. Pathologists work remotely. Studies span multiple sites and time zones. CROs share data with biopharma sponsors. Research teams collaborate with external consultants. The image management system is the platform through which all of this collaboration happens — which means its collaboration capabilities (or lack of them) directly constrain what your organization can offer.

An IMS with mature collaboration features — secure external sharing, role-based access for sponsors and partners, commenting and annotation tools that work across organizations, and the ability to present images to stakeholders without requiring them to install client software — becomes an enabler of new service models and partnership structures. An IMS that can't support external access, or that makes multi-site collaboration cumbersome, narrows what your organization can do and how competitive it can be.

For CROs in particular, this is a differentiator that clients increasingly notice and ask about. The ability to give a study sponsor real-time, secure access to images and annotations — without email attachments, without VPN complexity, without requiring IT involvement on the sponsor's side — is a meaningful competitive advantage.

The hidden cost of the wrong IMS

The direct costs of a poor IMS choice are visible: licensing fees, implementation costs, training time. The indirect costs are less visible but substantially larger.

• Productivity losses accumulate quietly. Pathologists spending extra time on navigation workarounds, IT staff managing manual file transfers, scientists reformatting data to move it between systems — none of this appears on an invoice, but it represents real organizational cost that compounds over time.
• Migration costs are often the most painful surprise. Labs that select an interim IMS with the intention of upgrading later frequently discover that migration is more complex, more expensive, and more disruptive than anticipated. Image libraries spanning hundreds of gigabytes, custom workflows built around a specific platform's quirks, and organizational habits built around a particular interface all create migration friction. The "temporary" solution becomes harder to leave.
• Compliance remediation can be the most acute cost of all. Discovering mid-audit that your IMS doesn't meet GLP audit trail requirements, or that your data integrity documentation has gaps, creates urgency that doesn't respect project timelines or budget cycles. Remediation under pressure is expensive. Remediation under regulatory scrutiny is worse.
• ‍Opportunity costs are the least visible and potentially the largest. A lab constrained by its IMS can't easily adopt a new scanner modality, integrate a promising new analysis tool, or offer new collaboration capabilities to clients. These aren't abstract losses — they're specific opportunities that go to organizations with more flexible infrastructure.

What strategic IMS selection looks like in practice

A strategic IMS decision doesn't mean evaluating hundreds of vendors or spending a year on requirements gathering. It means evaluating the right things at the right depth.

• Lead with integration requirements. Map the systems your IMS needs to connect to — scanners, analysis tools, LIMS — and validate those connections with each vendor before shortlisting. Integration claims that aren't backed by production deployments or documented API references deserve scrutiny.
• Stress-test compliance claims. If regulated workflows are in scope, ask vendors for validation documentation, audit trail architecture details, and customer references in regulated environments. "Configurable for compliance" is not the same as "validated for GLP."
• Involve end users in evaluation. Give pathologists and scientists hands-on time with shortlisted platforms in workflows that reflect their actual work. Their feedback is a leading indicator of adoption success.
• Model total cost of ownership (TCO), not just license cost. Include implementation, integration, training, IT overhead, and — critically — a realistic estimate of migration cost if the platform needs to change in three to five years. The cheapest license is rarely the lowest TCO.
• ‍Evaluate the vendor, not just the product. An IMS relationship is long-term. Assess the vendor's support model, roadmap transparency, and track record of delivering on commitments. A flashy product from an unreliable vendor is a risk.

The decision compounds over time

Every year you operate on your IMS, more data accumulates in it, more workflows are built around it, and more organizational habits form around its particular way of doing things. This is true of any enterprise system — and it means that the longer you stay on a platform, the more consequential the original decision becomes, for better or worse.

Labs that choose strategically — that select an IMS capable of growing with their workflows, adapting to new technology, and meeting compliance requirements without constant compensating effort — find that the platform becomes a genuine asset over time. It enables things rather than constraining them.

Labs that make the IMS decision opportunistically — choosing whatever was bundled with the scanner, whatever was cheapest upfront, or whatever required the least initial effort to implement — often find the opposite. The platform that seemed adequate at small scale reveals its limitations as workflows grow, and the cost of living with those limitations eventually exceeds the cost of replacing the platform.

The IMS decision is one of the few technology choices in digital pathology where getting it right from the start pays compounding returns. It's worth treating it that way.

Thinking through your IMS options? We're happy to help.
Book a PathcoreFlow demo →
‍Download the IMS Evaluation Checklist →

‍

This article is part of Pathcore's digital pathology resource hub. For related reading, see:

• Everything to Know About an Image Management System (IMS)
• The Complete Digital Pathology Stack: How Scanning, IMS, Image Analysis, and LIMS Work Together

‍